November 20, 2024
IQ-AI Ltd
("IQ-AI" or the
"Company")
Imaging
Biometrics Expands Distribution
Imaging Biometrics (IB), Elm Grove,
WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI) has renewed
its distribution agreement with GE HealthCare. This agreement aims
to expand the distribution of IB's advanced imaging solutions. GE
HealthCare will now sell IB Neuro and IB Delta T1 platforms
directly to both existing and new customers.
IB Neuro and IB Delta T1 maps are
frequently used together to assist in diagnosing, planning, and
monitoring treatment response for brain tumor patients. Delta T1
maps provide objective and rapid delineation of contrast-enhancing
regions, while IB Neuro generates magnetic resonance (MR) perfusion
images that accurately measure relative cerebral blood volume
(rCBV) using a proven contrast leakage correction algorithm. IB
Neuro's rCBV perfusion maps, derived from dynamic susceptibility
contrast MRI (DSC-MRI), are used for tumor assessment and have
demonstrated the ability to distinguish between true tumor regrowth
and normal treatment effects. Both maps are automatically generated
and quantitative, allowing for direct longitudinal comparison to
assess tumoral changes.
"This global distribution
arrangement allows us to introduce our products to GE HealthCare's
extensive customer base more rapidly," said Michael Schmainda, CEO
of IB. "We are excited about the immediate opportunities this
creates for GE HealthCare's sales and marketing teams."
Katie Anderson, Global MR
Visualization Product Manager added, "We are excited to expand our
collaboration with Imaging Biometrics to enable access for our
customers to these clinically important capabilities."
The revised agreement aims to
accelerate the adoption of IB's innovative imaging solutions,
benefiting healthcare providers and patients alike.
--ENDS-
The Directors of the Company accept
responsibility for the contents of this announcement.
For further information, please
contact:
|
IQ-AI Ltd
Trevor Brown/Dr Musella/Brett
Skelly/Michael Schmainda
Tel: 020 7469 0930
|
|
Peterhouse Capital Limited (Financial Adviser and Broker)
Tel: 020 7220 9797
|
About Imaging Biometrics® LLC
IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and
focuses on delivering quantitative imaging platforms and
therapeutics that transform how clinicians diagnose and treat
patients more efficiently and effectively. For more information
about Imaging Biometrics, visit the company's website at
www.imagingbiometrics.com. Follow
IB on X @IQAI_IB.
